Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is positioned for continued growth with an expanding product and service offerings, strategic initiatives, and a strong portfolio. However, competition and developing new diagnostic solutions may pose challenges in the future. The company has seen positive financial results for Q2, with increased revenue and EBITDA guidance, as well as growth in testing volume and strategic acquisitions and divestitures.

Bears say

CareDx is facing significant financial stress due to the limitations imposed by Medicare, resulting in a drastically reduced total addressable market for its testing services. Additionally, its expansion into the MRD and oncology diagnostics market may not be enough to offset the loss of revenue and stabilize the company's financial performance. However, limited competition in the market may provide some protection for CareDx in the short term, but investors should keep a close eye on Natera as a potential competitor in the future.

CareDx (CDNA) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 4 analysts, CareDx (CDNA) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.